PL3882244T3 - ZWIĄZEK, JEGO FARMACEUTYCZNIE DOPUSZCZALNA SÓL LUB IZOMER OPTYCZNY, SPOSÓB ICH WYTWARZANIA i ZAWIERAJĄCA JE, JAKO SKŁADNIK AKTYWNY, KOMPOZYCJA FARMACEUTYCZNA DO PROFILAKTYKI LUB LECZENIA CHORÓB WIRUSOWYCH - Google Patents
ZWIĄZEK, JEGO FARMACEUTYCZNIE DOPUSZCZALNA SÓL LUB IZOMER OPTYCZNY, SPOSÓB ICH WYTWARZANIA i ZAWIERAJĄCA JE, JAKO SKŁADNIK AKTYWNY, KOMPOZYCJA FARMACEUTYCZNA DO PROFILAKTYKI LUB LECZENIA CHORÓB WIRUSOWYCHInfo
- Publication number
- PL3882244T3 PL3882244T3 PL21152125.7T PL21152125T PL3882244T3 PL 3882244 T3 PL3882244 T3 PL 3882244T3 PL 21152125 T PL21152125 T PL 21152125T PL 3882244 T3 PL3882244 T3 PL 3882244T3
- Authority
- PL
- Poland
- Prior art keywords
- prevention
- compound
- treatment
- pharmaceutically acceptable
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20120146081 | 2012-12-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3882244T3 true PL3882244T3 (pl) | 2025-06-16 |
Family
ID=51732919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21152125.7T PL3882244T3 (pl) | 2012-12-14 | 2013-12-16 | ZWIĄZEK, JEGO FARMACEUTYCZNIE DOPUSZCZALNA SÓL LUB IZOMER OPTYCZNY, SPOSÓB ICH WYTWARZANIA i ZAWIERAJĄCA JE, JAKO SKŁADNIK AKTYWNY, KOMPOZYCJA FARMACEUTYCZNA DO PROFILAKTYKI LUB LECZENIA CHORÓB WIRUSOWYCH |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9790197B2 (pl) |
| EP (3) | EP2933254B1 (pl) |
| JP (1) | JP6293168B2 (pl) |
| KR (1) | KR101630243B1 (pl) |
| CN (1) | CN105121433B (pl) |
| DK (1) | DK3882244T3 (pl) |
| ES (2) | ES2863985T3 (pl) |
| FI (1) | FI3882244T3 (pl) |
| HR (1) | HRP20250341T1 (pl) |
| HU (1) | HUE071451T2 (pl) |
| LT (1) | LT3882244T (pl) |
| PL (1) | PL3882244T3 (pl) |
| PT (1) | PT3882244T (pl) |
| SI (1) | SI3882244T1 (pl) |
| WO (1) | WO2014092514A1 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12286423B2 (en) * | 2020-04-20 | 2025-04-29 | Novartis Ag | Antiviral 1,3-di-oxo-indene compounds |
| KR20230024887A (ko) * | 2020-04-20 | 2023-02-21 | 노파르티스 아게 | 항바이러스성 1,3-디-옥소-인덴 화합물 |
| CN112062693A (zh) * | 2020-09-23 | 2020-12-11 | 上海吉奉生物科技有限公司 | 一种2-(9h-芴-9-甲氧基羰基氨基)-3-甲基-2-丁烯酸的合成方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH583723A5 (pl) | 1972-12-18 | 1977-01-14 | Hoechst Ag | |
| GB1425295A (en) | 1974-01-23 | 1976-02-18 | Rizh Politekhn I | Alpha-aminoylidenephthalides and processes for their preparation |
| GB1533388A (en) | 1975-02-07 | 1978-11-22 | Creat | Ninhydrin-phenol condensation products their preparation and use as therapeutic agents |
| FR2392951A2 (fr) | 1975-02-07 | 1978-12-29 | Creat Lab | Nouveaux derives de la ninhydrine, leurs procedes de preparation et medicaments contenant ces derives |
| US3984552A (en) | 1975-02-24 | 1976-10-05 | Merck & Co., Inc. | 6-Oxo-7-substituted and 7,7-disubstituted-6H-indeno-[5,4-b]furan (and thiophene) carboxylic acids |
| GB8327598D0 (en) | 1983-10-14 | 1983-11-16 | Akzo Nv | Pharmacologically active diarylindane-13-diones |
| SE8902274D0 (sv) | 1989-06-22 | 1989-06-22 | Univ Cincinnati | Indenoidole compounds ii |
| CZ65393A3 (en) | 1990-10-16 | 1994-02-16 | Univ Bath | Indenoindole derivative, process of its preparation and pharmaceutical preparation in which said derivative is comprised |
| DE4035809A1 (de) * | 1990-11-10 | 1992-05-14 | Boehringer Mannheim Gmbh | Verwendung von thiazoloisoindolinon-derivaten als antivirale arzneimittel |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| JP2001089455A (ja) | 1999-09-17 | 2001-04-03 | Maruishi Pharmaceutical Co Ltd | ５，１０−ジヒドロ−１１Ｈ−インデノ〔１，２−ｂ〕キノリン−１０−オン誘導体 |
| US6541470B1 (en) | 1999-08-30 | 2003-04-01 | Maruishi Pharmaceutical Co., Ltd. | 1,2-disubstituted 1,4-dihydro-4-oxoquinoline compounds |
| US7371168B2 (en) | 2001-10-05 | 2008-05-13 | Igt | Gaming apparatus and method of gaming including interactive gaming symbols for producing different outcomes |
| WO2003082265A2 (en) * | 2002-04-02 | 2003-10-09 | Fujisawa Pharmaceutical Co | Pharmaceutical composition for treating or preventing virus infectious diseases |
| WO2004041201A2 (en) | 2002-11-01 | 2004-05-21 | Viropharma Incorporated | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases |
| EP1569928A4 (en) | 2002-11-08 | 2008-12-10 | Government Of The State Of Sar | THERAPEUTIC COMPOUNDS AND METHOD |
| ES2423800T3 (es) | 2003-03-28 | 2013-09-24 | Novartis Vaccines And Diagnostics, Inc. | Uso de compuestos orgánicos para la inmunopotenciación |
| EP2307440A4 (en) | 2008-07-01 | 2012-12-19 | Zacharon Pharmaceuticals Inc | HEPARAN SULFATE INHIBITORS |
| US20100261706A1 (en) | 2008-12-08 | 2010-10-14 | Inotek Pharmaceuticals Corporation | Substituted tetracyclic 1h-indeno [1,2-b]pyridine-2(5h)-one analogs thereof and uses thereof |
| EP2324820B1 (en) | 2009-11-04 | 2016-03-02 | Inopharm Limited | Stable fluindione composition comprising one or more antioxidant agents |
| JP5906309B2 (ja) * | 2011-06-16 | 2016-04-20 | コーリア リサーチ インスティテュート オブ ケミカル テクノロジー | インダノン誘導体、その薬学的に許容される塩又は光学異性体、その調製方法及びそれを活性成分として含有するウイルス疾患の予防又は治療用の医薬組成物 |
| US9346749B2 (en) * | 2011-06-16 | 2016-05-24 | Korea Research Institute Of Chemical Technology | 1,3-di-oxo-indene derivative, pharmaceutically acceptable salt or optical isomer thereof, preparation method thereof, and pharmaceutical composition containing same as an antiviral, active ingredient |
-
2013
- 2013-12-16 US US14/651,656 patent/US9790197B2/en active Active
- 2013-12-16 CN CN201380073105.3A patent/CN105121433B/zh active Active
- 2013-12-16 PT PT211521257T patent/PT3882244T/pt unknown
- 2013-12-16 HU HUE21152125A patent/HUE071451T2/hu unknown
- 2013-12-16 FI FIEP21152125.7T patent/FI3882244T3/fi active
- 2013-12-16 SI SI201332098T patent/SI3882244T1/sl unknown
- 2013-12-16 ES ES13862055T patent/ES2863985T3/es active Active
- 2013-12-16 ES ES21152125T patent/ES3018891T3/es active Active
- 2013-12-16 DK DK21152125.7T patent/DK3882244T3/da active
- 2013-12-16 EP EP13862055.4A patent/EP2933254B1/en active Active
- 2013-12-16 WO PCT/KR2013/011668 patent/WO2014092514A1/ko not_active Ceased
- 2013-12-16 EP EP21152125.7A patent/EP3882244B1/en active Active
- 2013-12-16 HR HRP20250341TT patent/HRP20250341T1/hr unknown
- 2013-12-16 EP EP25161547.2A patent/EP4585266A3/en active Pending
- 2013-12-16 JP JP2015547863A patent/JP6293168B2/ja active Active
- 2013-12-16 LT LTEP21152125.7T patent/LT3882244T/lt unknown
- 2013-12-16 KR KR1020130156409A patent/KR101630243B1/ko active Active
- 2013-12-16 PL PL21152125.7T patent/PL3882244T3/pl unknown
-
2017
- 2017-02-15 US US15/433,536 patent/US9951058B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140081687A (ko) | 2014-07-01 |
| JP6293168B2 (ja) | 2018-03-14 |
| KR101630243B1 (ko) | 2016-06-15 |
| EP4585266A3 (en) | 2025-09-17 |
| WO2014092514A1 (ko) | 2014-06-19 |
| US9790197B2 (en) | 2017-10-17 |
| US20150336920A1 (en) | 2015-11-26 |
| EP3882244A1 (en) | 2021-09-22 |
| US20170158684A1 (en) | 2017-06-08 |
| EP4585266A2 (en) | 2025-07-16 |
| EP3882244B1 (en) | 2025-03-05 |
| PT3882244T (pt) | 2025-04-04 |
| CN105121433B (zh) | 2018-01-23 |
| SI3882244T1 (sl) | 2025-07-31 |
| ES3018891T3 (en) | 2025-05-19 |
| ES2863985T3 (es) | 2021-10-13 |
| HUE071451T2 (hu) | 2025-08-28 |
| EP2933254A4 (en) | 2016-05-11 |
| JP2016504321A (ja) | 2016-02-12 |
| LT3882244T (lt) | 2025-05-12 |
| US9951058B2 (en) | 2018-04-24 |
| CN105121433A (zh) | 2015-12-02 |
| HRP20250341T1 (hr) | 2025-05-23 |
| FI3882244T3 (fi) | 2025-04-11 |
| DK3882244T3 (da) | 2025-03-24 |
| HK1216253A1 (en) | 2016-10-28 |
| EP2933254B1 (en) | 2021-01-20 |
| EP2933254A1 (en) | 2015-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014KN00948A (pl) | ||
| ZA201707096B (en) | Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient | |
| IL231226A (en) | Compounds and preparations as kinase c-kit inhibitors, pharmaceutical preparations containing them and their use in the preparation of medicines for the treatment of diseases | |
| EA033544B1 (ru) | Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret) | |
| WO2013188273A8 (en) | Topical ophthalmological pharmaceutical composition containing axitinib | |
| EA201590520A1 (ru) | Фармацевтическая композиция с покрытием, содержащая регорафениб | |
| WO2013100567A8 (en) | Phenyl carbamate compounds for use in alleviating or treating pain and neuropathic pain | |
| EP3176163A4 (en) | Novel indene derivative, preparation method for same, and pharmaceutical composition, for preventing or treating retinal diseases, containing same as active ingredient | |
| WO2014016754A3 (en) | Pharmaceutical compositions of proton pump inhibitor | |
| EP3093023A4 (en) | Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient | |
| ZA201500362B (en) | Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient | |
| EP3138834A4 (en) | Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing same as active ingredient | |
| EP2871187A4 (en) | A NEW CONNECTION OR PHARMACEUTICALALLY SALT AND PHARMACEUTICAL COMPOSITION THEREFOR AS AN ACTIVE SUBSTANCE | |
| PT2722322T (pt) | Derivado de 1,3-di-oxo-indeno, seu sal farmaceuticamente aceitável ou isómero ótico, seu método de preparação, e composição farmacêutica contendo o mesmo como ingrediente ativo, antiviral | |
| PT3882244T (pt) | Composto, sal farmaceuticamente aceitável ou isómero ótico do mesmo, método para a sua preparação e composição farmacêutica para prevenção ou tratamento de doenças virais que contenha o mesmo como ingrediente ativo | |
| IL230907A0 (en) | Salt and formations of a pyrazolopyrimidine compound, a medical composition that includes the above, and a preparation and use process for them | |
| WO2013188279A8 (en) | Topical ophthalmological pharmaceutical composition containing cediranib | |
| IL238071B (en) | Pharmaceutical composition of 1-adamantylethyloxy-3-morpholino-2-propanol or pharmaceutically acceptable salts thereof for the treatment of cardiovascular disease | |
| ZA201801839B (en) | Pharmaceutical composition for preventing and treating liver diseases, containing, as active ingredient, cromolyn or pharmaceutically acceptable salt thereof | |
| MX350516B (es) | Compuestos de anillo fusionado que contienen nitrogeno como antagonistas crth2. | |
| HK40099449B (zh) | 一种化合物的制备方法及其纯化以用作活性药物成分 | |
| CA3293510A1 (en) | Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases | |
| IN2014DN10683A (pl) | ||
| PL3611158T3 (pl) | 1,3-di-okso-indenowa pochodna, jej farmaceutycznie dopuszczalna sól lub izomer optyczny, sposób jej wytwarzania i kompozycja farmaceutyczna ją zawierająca jako przeciwwirusowy składnik czynny | |
| EP3187179A4 (en) | Pharmaceutical composition for prophylaxis and/or treatment of corneal and conjunctival diseases or presbyopia containing stilbene compound as active ingredient |